Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Pannexin-1 channels promotes CD8+ T cell effector and memory responses through distinct metabolic pathways
Banuelos, Alma , Vardam-Kaur, Trupti , Gabaldon-Parish, Maria, Dijk, Sarah van , Zhou, Maggie H. , Wanhainen, Kelsey M. , Macedo, Bruna de Gois , Salgado, Caio Loureiro , Santiago-Carvalho, Igor , Peng, Changwei , Jameson, Stephen C. , Silva, Henrique Borges da

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 226.15-226.15

10.4049/jimmunol.210.supp.226.15 Get It

Abstract Sensing of extracellular metabolites controls CD8+ T cell function. Their accumulation can occur through export by specialized molecules, such as the release channel Pannexin-1 (Panx1). Here, we report that T cell-specific Panx1 is needed for efficient CD8+ T cell responses to viral infection and cancer. Panx1 favors both the expansion of effector CD8+ T cells and the survival of memory CD8+ T cells. Our data suggests that, while memory CD8+ T cells require Panx1 for mitochondrial function, Panx1 promotes the glycolytic pathway in effector CD8+ T cells. Panx1 promotes memory CD8+ T cell survival together with the eATP sensor P2RX7. However, Panx1 induces effector CD8+ T cells independently of eATP. Rather, we found an unexpected link between Panx1, lactate export and the activation of effector CD8+ T cells. Therefore, Panx1 regulates effector and memory CD8+ T cells through export of distinct metabolites and by engaging different intracellular pathways.
Cell-specific P2RX7 promotes the longevity of lung tissue-resident helper CD4 T cells in response to influenza infection
Vardam-Kaur, Trupti , Dijk, Sarah van , Santiago-Carvalho, Igor , Macedo, Bruna de Gois , Salgado, Caio Loureiro , Silva, Henrique Borges da

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 156.07-156.07

10.4049/jimmunol.210.supp.156.07 Get It

Abstract Development of universal influenza (flu) vaccines requires better knowledge of lung-resident immune responses. That includes flu-specific CD4 T cells, which establish long-term lung residency and induce a diversified local protective response to subsequent infection. Tissue-resident helper (Trh) cells are a subset of lung-resident CD4 T cells that share phenotypic and functional features with follicular helper cells (Tfh). Trh cells serve to amplify lung-resident immune responses, and express high levels of the extracellular ATP (eATP) sensor P2RX7. Considering that eATP levels in the lung increase in response to flu infection, we used T cell-specific P2RX7-knockout (KO) mice to test the role of P2RX7 for CD4 T cell responses to flu. During acute phase of infection, we found that P2RX7 promotes the accumulation of flu-specific CD4 T cells inside the lung tissue. Moreover, P2RX7 promoted this establishment via induction of CXCR3 upregulation. Despite no specific defects in the Trh pool at the acute phase, T cell-specific P2RX7-KO led to a progressive decay of Trh cells. Consequently, lungs of T cell-P2RX7-KO mice had reduced lung B cell responses. Our single-cell RNAseq of lung flu-specific CD4 T cells showed reduced expression of cell survival and mitochondrial genes in P2RX7-KO Trh cells. Our findings suggest that lung eATP sensing by CD4 T cells induces lung-resident CD4 T cell accumulation in response to flu, impacting the survival of specific lung CD4 T cell subsets. National Institute of Allergy and Infectious Diseases (NIAID) (H.BdS.: R00 AI139381, R01 AI170649).
P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
Abonour, Rafat , Rifkin, Robert M. , Gasparetto, Christina, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Toomey, Kathleen, Tang, Yuexin , Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang , Ailawadhi, Sikander , Lee, Hans C. , Wagner, Lynne I. , Hardin, James W. , Jagannath, Sundar

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e52503e2

10.1097/01.hs9.0000970564.52503.e2 Get It

P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY
Popat, Rakesh , Kleinman, David , Perera, Sue, Gorsh, Boris , Mulnick, Sarah, Alicia, Oneill, Hanna, Maya, Molinari, Alexa , Gelhorn, Heather L. , Popat, Rakesh , Ailawadhi, Sikander , Thomas, Caitlin , Ross, Melissa

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e989881c

10.1097/01.hs9.0000970648.98988.1c Get It

P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM START OF ENROLLMENT
Eyre, Toby A. , Ujjani, Chaitra S. , Alencar, Alvaro J. , Lewis, David , Maddocks, Kami J. , Munir, Talha, Balbas, Minna, Tsai, Donald E. , Wang, Chunxiao , Wang, Michael , Shah, Nirav N. , Jurczak, Wojciech , Zinzani, Pier Luigi , Cheah, Chan Y. , Izutsu, Koji , Ma, Shuo , Flinn, Ian W. , Patel, Krish , Wang, Yucai , Zelenetz, Andrew D.

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e45636b5

10.1097/01.hs9.0000971244.45636.b5 Get It

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
Engstrom, Lars D. , Aranda, Ruth , Waters, Laura , Moya, Krystal , Bowcut, Vickie , Vegar, Laura , Trinh, David , Hebbert, Allan , Smith, Christopher R. , Kulyk, Svitlana , Lawson, J. David , He, Leo , Hover, Laura D. , Hallin, Jill , Vanderpool, Darin , Briere, David M. , Blaj, Alice , Arbour, Kathryn C. , Jänne, Pasi A. , Papadopoulos, Kyriakos P. , Henry, Jason T. , Leventakos, Konstantinos , Christensen, James G. , Shazer, Ronald , Olson, Peter , Fernandez-Banet, Julio , Hallin, Jill , Vanderpool, Darin , Briere, David M , Blaj, Alice , Marx, Matthew A , Rodon, Jordi , Offin, Michael , Arbour, Kathryn C , Johnson, Melissa L , Kwiatkowski, David J. , Jänne, Pasi A , Haddox, Candace L , Papadopoulos, Kyriakos P , Henry, Jason T , Leventakos, Konstantinos , Christensen, James G , Shazer, Ronald , Olson, Peter , Johnson, Melissa L. , Haddox, Candace L.

Mayo Clinic

Cancer Discovery | August 8, 2023 | Volume: 13 | Issue: 11 | Pages: 2412-2431

10.1158/2159-8290.cd-23-0669 | PMID 37552839 Get It

Abstract Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selecti­vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study. Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293
P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
Cohen, Jonathon B. , Eyre, Toby A. , Woyach, Jennifer A. , Seymour, John F. , Wang, Michael , Loubert, Angély , Hess, Lisa M. , Abada, Paolo, Mato, Anthony R. , Roeker, Lindsey E. , Cheah, Chan Y. , Patel, Krish , Wang, Yucai , Payakachat, Nalin , Ghia, Paolo

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e34270c5

10.1097/01.hs9.0000971344.34270.c5 Get It

Age‐related histopathological findings in temporal arteries
Kendziora, Ryan W., Maleszewski, Joseph J. , Lin, Peter T. , Aubry, Marie‐Christine, Weyand, Cornelia M. , Jenkins, Sarah M. , Lo, Ying‐Chun , Bois, Melanie C. , Lo, Ying-Chun , Aubry, Marie-Christine, Warrington, Kenneth J.

Mayo Clinic

Histopathology | August 8, 2023 | Volume: 83 | Issue: 5 | Pages: 782-790

10.1111/his.15019 | PMID 37551446 Get It

AimsGiant cell arteritis (GCA) is a systemic vasculitis affecting medium and large arteries in patients aged over 50 years. Involvement of temporal arteries (TA) can lead to complications such as blindness and stroke. While the diagnostic gold standard is temporal artery biopsy (TAB), comorbidities and age‐related changes can make interpretation of such specimens difficult. This study aims to establish a baseline of TA changes in subjects without GCA to facilitate the interpretation of TAB.Methods and resultsBilateral TA specimens were collected from 100 consecutive eligible postmortem examinations. Subjects were divided into four age groups and specimens semiquantitatively evaluated for eccentric intimal fibroplasia, disruption and calcification of the internal elastic lamina (IEL), medial attenuation and degree of lymphocytic inflammation of the peri‐adventitia, adventitia, media and intima. The individual scores of intimal fibroplasia, IEL disruption and medial attenuation were added to yield a ‘combined score (CS)’. Seventy‐eight 78 decedents were included in the final analysis following exclusion of 22 individuals for either lack of clinical information or inability to collect TA tissue. A total of 128 temporal artery specimens (50 bilateral from individual decedents, 28 unilateral) were available for examination. Intimal proliferation, IEL loss, IEL calcification and CS increased with age in a statistically significant fashion. Comparison of the oldest age group with the others showed statistically significant differences, although this was not uniformly preserved in comparison between the three youngest groups.ConclusionSenescent arterial changes and healed GCA exhibit histological similarity and such changes increase proportionally with age. The CS demonstrates significant association with age overall and represents a potential avenue for development to ‘normalise’ TA biopsies from older individuals.
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Pappo, Alberto S. , Acquazzino, Melissa , Barnett, Marie , Casey, Robert, Choo, Sun , Dinner, Shira, Fair, Douglas , Federman, Noah , Folbrecht, Jeanelle , Gandhi, Shipra , Germann, Julie N. , Goldsby, Robert E. , Hayashi, Robert J. , Huang, Mary , Jacobs, Linda A. , Lee‐Miller, Cathy , Link, Michael P., Lustberg, Maryam B. , Malogolowkin, Marcio H., Oeffinger, Kevin C. , Pratilas, Christine A. , Mehren, Margaret von , Yeager, Nicholas D. , Hang, Lisa, von Mehren, Margaret , Lustberg, Maryam , Bhatia, Smita , Allen‐Rhoades, Wendy , Borinstein, Scott C. , Chugh, Rashmi , Ermoian, Ralph P. , Huang, Alex Yee-Chen , Livingston, J. Andrew , Reed, Damon R. , Skiles, Jodi L. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 851-880

10.6004/jnccn.2023.0040 | PMID 37549914 Get It

This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.